Literature DB >> 18981257

Sequential B-cell epitopes of Bacillus anthracis lethal factor bind lethal toxin-neutralizing antibodies.

Melissa L Nguyen1, Sherry R Crowe, Sridevi Kurella, Simon Teryzan, Brian Cao, Jimmy D Ballard, Judith A James, A Darise Farris.   

Abstract

The bipartite anthrax lethal toxin (LeTx) consisting of protective antigen (PA) and lethal factor (LF) is a major virulence factor contributing to death from systemic Bacillus anthracis infection. The current vaccine elicits antibodies directed primarily to PA; however, in experimental settings serologic responses to LF can neutralize LeTx and contribute to protection against infection. The goals of the present study were to identify sequential B-cell epitopes of LF and to determine the capacity of these determinants to bind neutralizing antibodies. Sera of recombinant LF-immunized A/J mice exhibited high titers of immunoglobulin G anti-LF reactivity that neutralized LeTx in vitro 78 days after the final booster immunization and protected the mice from in vivo challenge with 3 50% lethal doses of LeTx. These sera bound multiple discontinuous epitopes, and there were major clusters of reactivity on native LF. Strikingly, all three neutralizing, LF-specific monoclonal antibodies tested bound specific peptide sequences that coincided with sequential epitopes identified in polyclonal antisera from recombinant LF-immunized mice. This study confirms that LF induces high-titer protective antibodies in vitro and in vivo. Moreover, the binding of short LF peptides by LF-specific neutralizing monoclonal antibodies suggests that generation of protective antibodies by peptide vaccination may be feasible for this antigen. This study paves the way for a more effective anthrax vaccine by identifying discontinuous peptide epitopes of LF.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18981257      PMCID: PMC2612257          DOI: 10.1128/IAI.00788-08

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  51 in total

1.  The Protein Data Bank.

Authors:  H M Berman; J Westbrook; Z Feng; G Gilliland; T N Bhat; H Weissig; I N Shindyalov; P E Bourne
Journal:  Nucleic Acids Res       Date:  2000-01-01       Impact factor: 16.971

2.  Mapping the anthrax protective antigen binding site on the lethal and edema factors.

Authors:  D Borden Lacy; Michael Mourez; Alexandre Fouassier; R John Collier
Journal:  J Biol Chem       Date:  2001-11-19       Impact factor: 5.157

3.  Crystal structure of the anthrax lethal factor.

Authors:  A D Pannifer; T Y Wong; R Schwarzenbacher; M Renatus; C Petosa; J Bienkowska; D B Lacy; R J Collier; S Park; S H Leppla; P Hanna; R C Liddington
Journal:  Nature       Date:  2001-11-08       Impact factor: 49.962

4.  Large-scale production of protective antigen of Bacillus anthracis in anaerobic cultures.

Authors:  M PUZISS; L C MANNING; J W LYNCH; I ABELOW; G G WRIGHT
Journal:  Appl Microbiol       Date:  1963-07

5.  Early events in lupus humoral autoimmunity suggest initiation through molecular mimicry.

Authors:  Micah T McClain; Latisha D Heinlen; Gregory J Dennis; Jon Roebuck; John B Harley; Judith A James
Journal:  Nat Med       Date:  2004-12-26       Impact factor: 53.440

6.  Induction of autoimmunity by multivalent immunodominant and subdominant T cell determinants of La (SS-B).

Authors:  A D Farris; L Brown; P Reynolds; J B Harley; J A James; R H Scofield; J McCluskey; T P Gordon
Journal:  J Immunol       Date:  1999-03-01       Impact factor: 5.422

Review 7.  Anthrax: forms, symptoms and treatment.

Authors:  Philip Woodrow
Journal:  Nurs Stand       Date:  2003 Aug 13-19

8.  Antibodies to anthrax toxin in humans and guinea pigs and their relevance to protective immunity.

Authors:  P C Turnbull; S H Leppla; M G Broster; C P Quinn; J Melling
Journal:  Med Microbiol Immunol       Date:  1988       Impact factor: 3.402

9.  Anthrax protective antigen forms oligomers during intoxication of mammalian cells.

Authors:  J C Milne; D Furlong; P C Hanna; J S Wall; R J Collier
Journal:  J Biol Chem       Date:  1994-08-12       Impact factor: 5.157

10.  Detoxified lethal toxin as a potential mucosal vaccine against anthrax.

Authors:  Qingfu Xu; Mingtao Zeng
Journal:  Clin Vaccine Immunol       Date:  2008-02-06
View more
  18 in total

1.  Select human anthrax protective antigen epitope-specific antibodies provide protection from lethal toxin challenge.

Authors:  Sherry R Crowe; Linda L Ash; Renata J M Engler; Jimmy D Ballard; John B Harley; A Darise Farris; Judith A James
Journal:  J Infect Dis       Date:  2010-07-15       Impact factor: 5.226

2.  Anthrax vaccination induced anti-lethal factor IgG: fine specificity and neutralizing capacity.

Authors:  Sherry R Crowe; Lori Garman; Renata J M Engler; A Darise Farris; Jimmy D Ballard; John B Harley; Judith A James
Journal:  Vaccine       Date:  2011-03-21       Impact factor: 3.641

3.  Human monoclonal antibodies generated following vaccination with AVA provide neutralization by blocking furin cleavage but not by preventing oligomerization.

Authors:  Kenneth Smith; Sherry R Crowe; Lori Garman; Carla J Guthridge; Jennifer J Muther; Emily McKee; Nai-Ying Zheng; A Darise Farris; Joel M Guthridge; Patrick C Wilson; Judith A James
Journal:  Vaccine       Date:  2012-03-14       Impact factor: 3.641

Review 4.  Immunity to ricin: fundamental insights into toxin-antibody interactions.

Authors:  Joanne M O'Hara; Anastasiya Yermakova; Nicholas J Mantis
Journal:  Curr Top Microbiol Immunol       Date:  2012       Impact factor: 4.291

5.  Noninvasive imaging technologies reveal edema toxin as a key virulence factor in anthrax.

Authors:  Fabien Dumetz; Grégory Jouvion; Huot Khun; Ian Justin Glomski; Jean-Philippe Corre; Clémence Rougeaux; Wei-Jen Tang; Michèle Mock; Michel Huerre; Pierre Louis Goossens
Journal:  Am J Pathol       Date:  2011-06       Impact factor: 4.307

6.  Stochastic humoral immunity to Bacillus anthracis protective antigen: identification of anti-peptide IgG correlating with seroconversion to Lethal Toxin neutralization.

Authors:  Eric K Dumas; Melissa L Nguyen; Philip M Cox; Heidi Rodgers; Joanne L Peterson; Judith A James; A Darise Farris
Journal:  Vaccine       Date:  2013-02-13       Impact factor: 3.641

7.  An anthrax subunit vaccine candidate based on protective regions of Bacillus anthracis protective antigen and lethal factor.

Authors:  Les W Baillie; Theresa B Huwar; Stephen Moore; Gabriela Mellado-Sanchez; Liliana Rodriguez; Brendan N Neeson; Helen C Flick-Smith; Dominic C Jenner; Helen S Atkins; Rebecca J Ingram; Danny M Altmann; James P Nataro; Marcela F Pasetti
Journal:  Vaccine       Date:  2010-08-04       Impact factor: 3.641

8.  Neutralizing monoclonal antibodies directed against defined linear epitopes on domain 4 of anthrax protective antigen.

Authors:  Cassandra D Kelly-Cirino; Nicholas J Mantis
Journal:  Infect Immun       Date:  2009-08-24       Impact factor: 3.441

9.  Unique Inflammatory Mediators and Specific IgE Levels Distinguish Local from Systemic Reactions after Anthrax Vaccine Adsorbed Vaccination.

Authors:  Lori Garman; Kenneth Smith; Emily E Muns; Cathy A Velte; Christina E Spooner; Melissa E Munroe; A Darise Farris; Michael R Nelson; Renata J M Engler; Judith A James
Journal:  Clin Vaccine Immunol       Date:  2016-08-05

10.  The major neutralizing antibody responses to recombinant anthrax lethal and edema factors are directed to non-cross-reactive epitopes.

Authors:  Melissa L Nguyen; Simon Terzyan; Jimmy D Ballard; Judith A James; A Darise Farris
Journal:  Infect Immun       Date:  2009-08-31       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.